Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications.

导出 OA

翻译打印收藏纠错

作者： Francesca,Ligorio ^[1] ; Luca,Zambelli ^[2] ; Giovanni,Fucà ^[2] ; Riccardo,Lobefaro ^[2] ; Marzia,Santamaria ^[3] ; Emma,Zattarin ^[2] ; Filippo,de Braud ^[2] ; Claudio,Vernieri ^[1]

作者单位： Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy. ^[1] Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ^[2] Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milan, Italy. ^[3]

关键词 BMI HER2+ BC anti-HER2 drugs clinical outcomes molecular mechanisms

DOI 10.1177/17588359221079123

PMID 35281350

发布时间 2022-03-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Therapeutic advances in medical oncology

2022年14卷

17588359221079123页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications.

Therapeutic advances in medical oncology

相似文献

Therapeutic advances in medical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications.

Therapeutic advances in medical oncology

相似文献

Therapeutic advances in medical oncology

相关期刊

检索历史清除